MedWorm: Cialis

Healthy People Co. Issues a Voluntary Recall of Specific Lots of the Dietary Supplements Found to Contain Undeclared Drug Ingredients

Food and Drug Administration — Sat, 04 Feb 2012 21:11:00 +0100

Healthy People Co. announced today that it is conducting a voluntary nationwide recall of the company’s dietary supplements sold under the brand names Healthy People Co. specific to the following Lot Numbers. Healthy People Co. is conducting a voluntary recall because FDA lab analysis has confirmed the presence of Sibutramine and Tadalafil, making these products unapproved new drugs. (Source: Food and Drug Administration)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Treating Erectile Dysfunction and Central Neurological Diseases with Oral Phosphodiesterase Type 5 Inhibitors. Review of the Literature

The Journal of Sexual Medicine — Fri, 03 Feb 2012 05:00:00 +0100

Conclusions. PDE5 represent first line ED therapy only for SCI patients, though treatment results through meta‐analysis were not possible. Encouraging results are reported for Parkinson's and MS patients. PDE5 use for other CND patients is limited for various reasons, such as ED and concomitant libido impairment caused by depression and/or sexual endocrinology dysfunctions, and because PDE5 may cause a worsening of neurological illness. Medical centers staffed by health professionals able to counsel patients on the possible use of PDE5 are needed. Lombardi G, Nelli F, Celso M, Mencarini M, and Del Popolo G. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature. J Sex Med **;**:**–**. (Source: The Journ...

Type B aortic dissection after the use of tadalafil.

The Annals of Thoracic Surgery — Tue, 31 Jan 2012 04:18:33 +0100

This report and three other cases add a new dimension to the known predisposing factors such as chronic systemic hypertension, hereditary connective tissue diseases- and congenital aortic valve diseases. However, the precise role of phosphodiesterase type 5 inhibitors in the pathophysiology of aortic dissection remains unknown. PMID: 22269733 [PubMed - in process] (Source: The Annals of Thoracic Surgery)

Selective Class I Histone Deacetylase Inhibition Suppresses Hypoxia-Induced Cardiopulmonary Remodeling Through an Antiproliferative Mechanism.

Circulation Research — Thu, 26 Jan 2012 05:00:00 +0100

Conclusions:By targeting distinct pathogenic mechanisms, isoform-selective HDAC inhibitors have potential as novel therapeutics for pulmonary hypertension that will complement vasodilator standards of care. PMID: 22282194 [PubMed - as supplied by publisher] (Source: Circulation Research)

Type B Aortic Dissection After the Use of Tadalafil [CASE REPORTS]

The Annals of Thoracic Surgery — Tue, 24 Jan 2012 05:00:00 +0100

This report and three other cases add a new dimension to the known predisposing factors such as chronic systemic hypertension, hereditary connective tissue diseases– and congenital aortic valve diseases. However, the precise role of phosphodiesterase type 5 inhibitors in the pathophysiology of aortic dissection remains unknown. (Source: The Annals of Thoracic Surgery)

Efficacy of tadalafil in chronic hypobaric hypoxia–induced pulmonary hypertension: possible mechanisms

Fundamental and Clinical Pharmacology — Fri, 20 Jan 2012 18:16:16 +0100

AbstractThe present study was carried out to investigate the effects of long‐acting phosphodiesterase five inhibitor, tadalafil, on pulmonary hypertension induced by chronic hypobaric hypoxia in rats. Adult Albino Wistar rats were exposed to 2 weeks of hypobaric hypoxia for 8 h daily and treated with tadalafil or tempol, a standard antioxidant agent. Right ventricular systolic pressure (RVSP) was taken as an index for pulmonary arterial pressure; malondialdehyde, reduced glutathione and superoxide dismutase were chosen as the markers of oxidative stress; serum tumour necrosis factor alpha (TNF‐α) levels and inflammatory changes in lungs were assessed for inflammation. Chronic hypobaric hypoxia was found to induce pulmonary hypertension, as it significantly (P < 0.001) incre...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Effect of atorvastatin on erectile functions in comparison with regular tadalafil use. A prospective single-blind study

International Urology and Nephrology — Wed, 18 Jan 2012 06:59:32 +0100

Conclusion Tadalafil 20 mg three times/week shows better results than 10 mg atorvastatin daily. Atorvastatin alone seems to improve EF compared to not using any medication, and this significance is more prominent in patients with supranormal serum lipid levels. Further studies with subgroups of different serum lipid levels should be conducted. Content Type Journal ArticleCategory Urology – Original PaperPages 1-5DOI 10.1007/s11255-012-0126-zAuthors Mehmet İlker Gokce, Department of Urology, Ankara University School of Medicine, Adnan Saygun Caddesi, Altındağ, Ankara, TurkeyÖmer Gülpınar, Department of Urology, Ankara University School of Medicine, Adnan Saygun Caddesi, Altındağ, Ankara, TurkeyErdem Öztürk, Department of Urology, Ankara Universi...

FDA approves drugs for BPH, AF

Modern Medicine — Sun, 15 Jan 2012 05:00:00 +0100

FDA has approved tadalafil to treat benign prostatic hyperplasia in patients with or without erectile dysfunction and rivaroxaban to reduce the risk of stroke in patients with nonvalvular atrial fibrillation. (Source: Modern Medicine)

Crystal engineering of multiple-component organic solids: Pharmaceutical cocrystals of tadalafil with persistent hydrogen bonding motifs

RSC - CrystEngComm latest articles — Mon, 26 Dec 2011 06:12:46 +0100

CrystEngComm, 2012, Advance ArticleDOI: 10.1039/C2CE06574F, CommunicationDavid R. Weyna, Miranda L. Cheney, Ning Shan, Mazen Hanna, Lukasz Wojtas, Michael J. ZaworotkoThree tadalafil cocrystals exhibit persistent supramolecular chains that accept additional hydrogen bonds from the OH moieties of the respective coformers.To cite this article before page numbers are assigned, use the DOI form of citation above.The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - CrystEngComm latest articles)

Man Gets 13 Months in Fake-pill Ring

Drugs.com - Pharma News — Tue, 20 Dec 2011 11:12:47 +0100

From Houston Chronicle (TX) (December 20, 2011) Dec. 20--The leader of a Houston-based ring that illegally imported thousands of counterfeit Viagra and Cialis pills from China and sold the erectile-dysfunction remedies as the real deal... (Source: Drugs.com - Pharma News)

CIALIS (Tadalafil) Tablet, Film Coated [Physicians Total Care, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 15 Dec 2011 05:00:00 +0100

Updated Date: Dec 15, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

CIALIS (Tadalafil) Tablet, Film Coated [Eli Lilly And Company]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 14 Dec 2011 05:00:00 +0100

Updated Date: Dec 14, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Norvir 100mg film-coated tablets (ritonavir)- Revised SPC

NeLM - SPC Changes — Wed, 14 Dec 2011 05:00:00 +0100

Source: eMC (electronic Medicines Compendium) Area: Other Library Updates > SPC Changes There have been significant updates to several sections of the SPC, including the following: Change to section 4.5 - Interaction with other medicinal products and other forms of interaction Interaction statements have been added for fentanyl, dasatinib, nilotinib, tadalafil, bosentan and colchicine. Please refer to SPC link below for full information on all changes. (Source: NeLM - SPC Changes)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

South Central Priorities Committee recommends limiting prescriptions of erectile dysfunction drugs

NeLM - News — Thu, 08 Dec 2011 05:00:00 +0100

Source: BBC Health News, South Central Priorities Committee Area: News According to a BBC Health news report, GPs in Milton Keynes, Oxfordshire, Berkshire East, Berkshire West and Buckinghamshire, are being urged to limit prescriptions of erectile dysfunction drugs under new guidelines from the South Central Priorities Committee. The Committee had considered the evidence of clinical and cost-effectiveness, and the financial impact on the health economy of such treatments and made the following recommendations: 1. Treatment with phosphodiesterase type-5 inhibitors (sildenafil, vardenafil and tadalafil) at the minimum effective dose is recommended for the groups of patients identified in Health Service Circular (HSC) 1999/1771 at a maximum frequency of dosing of two ti...

New Benefits of Blockbuster Drug Cialis Discovered; Sales Expected To...

PRWeb: Medical Pharmaceuticals — Thu, 01 Dec 2011 19:16:33 +0100

Recent Research Supervised by the FDA Indicates Treatment with the Erectile Dysfunction Drug Tadalafil (Cialis) is Also Effective in the Treatment of Benign Prostatic Hyperplasia (BPH)....(PRWeb November 30, 2011)Read the full story at http://www.prweb.com/releases/2011/11/prweb8802338.htm (Source: PRWeb: Medical Pharmaceuticals)

Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure.

The Annals of Pharmacotherapy — Thu, 01 Dec 2011 05:00:00 +0100

CONCLUSIONS: Based on current studies, sildenafil appears to be well tolerated and can improve markers of cardiovascular and pulmonary function in patients with HF. PDE5 inhibitors may be a therapeutic option for patients who cannot tolerate standard therapy for HF or who remain symptomatic with standard therapy. Larger long-term trials are necessary to better understand the role of PDE5 inhibitors in HF. PMID: 22116990 [PubMed - in process] (Source: The Annals of Pharmacotherapy)

Simultaneous analysis of sildenafil, vardenafil, tadalafil, and their desalkyl metabolites in human whole blood and urine by isotope dilution LC–MS–MS

Forensic Toxicology — Mon, 28 Nov 2011 16:50:56 +0100

In this study, we established a detailed procedure for simultaneous analysis of typical ED drugs (sildenafil, vardenafil, tadalafil) and their metabolites in human blood and urine by isotope dilution liquid chromatography-tandem mass spectrometry (LC–MS–MS). Each sample of whole blood and urine containing the three ED treatment drugs, their metabolites, and deuterated internal standards (ISs) was diluted with alkalinized water, loaded onto an Oasis HLB cartridge, washed with dilute ammonium hydroxide solution, and eluted with chloroform. The eluate was acidified with methanol and concentrated HCl and evaporated to dryness. The resulting residue was reconstituted with methanol and mobile phase solution, and 5 μl of the solution was injected into an LC–MS–MS instrument. T...

Immunohistochemical and functional characterization of nitric oxide signaling pathway in isolated aorta from Crotalus durissus terrificus.

Comparative biochemistry and physiology. Toxicology and pharmacology : CBP — Mon, 21 Nov 2011 05:00:00 +0100

Authors: Mónica FZ, Rojas-Moscoso J, Porto M, Schenka A, Antunes E, Cogo JC, De Nucci G Abstract We characterized the nitric oxide (NO)-cyclic GMP-phosphodiesterase-5 (PDE5) pathway in Crotalus durissus terrificus aorta. Concentration responses curves to acetylcholine (ACh), sodium nitroprusside (SNP), BAY41-2272 (soluble guanylyl cyclase [sGC] stimulator), BAY60-2770 (sGC activator) and tadalafil (PDE5 inhibitor) were constructed in phenylephrine (10μM)-precontracted tissues with intact (E(+)) or denuded (E(-)) endothelium. ACh (0.001-10μM) and SNP (0.0001-10μM) relaxed aorta, which were reduced by the NO synthase (L-NAME,100μM) or the sGC inhibitors (ODQ, 10μM). Tadalafil (0.0001-10μM) relaxed E(+) rings with potency (pEC(50)) and maximal response (E(max)) values of 7.34±...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial.

International Journal of Andrology — Tue, 15 Nov 2011 05:00:00 +0100

In conclusion extracorporeal shock wave therapy plus tadalafil 5 mg once daily may represent a valid conservative strategy for the management of patients with Peyronie's disease and erectile dysfunction. PMID: 22085227 [PubMed - as supplied by publisher] (Source: International Journal of Andrology)

Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trial

International Journal of Andrology — Tue, 15 Nov 2011 05:00:00 +0100

In conclusion extracorporeal shock wave therapy plus tadalafil 5 mg once daily may represent a valid conservative strategy for the management of patients with Peyronie’s disease and erectile dysfunction. (Source: International Journal of Andrology)

Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries.

European Journal of Pharmacology — Wed, 09 Nov 2011 05:00:00 +0100

In conclusion, PDE5 inhibitors applied luminally had minor contractile effect, whereas abluminal sildenafil induced middle cerebral artery dilatation above therapeutic levels. In vivo, sildenafil dilated middle meningeal artery concomitant with a reduction in blood pressure. Tadalafil had no dilatory effects. PDE5 inhibitors show differential vascular activity in cerebral arteries from healthy animals; arterial dilatation is seen primarily above therapeutic levels. Such findings support clinical studies showing no vasodilator effects of sildenafil on cerebral arteries in healthy subjects. PMID: 22094063 [PubMed - as supplied by publisher] (Source: European Journal of Pharmacology)

Tadalafil alters energy metabolism in C2C12 skeletal muscle cells.

Acta Biochim Pol — Sat, 05 Nov 2011 13:00:03 +0100

Authors: Sabatini S, Sgrò P, Duranti G, Ceci R, Luigi LD Abstract Phosphodiesterases (PDEs) are a family of enzymes that hydrolyze cyclic nucleotides, thereby modulating cell functions. Three highly selective PDE5 inhibitors (PDE5i), sildenafil, vardenafil and tadalafil, have been developed for treatment of erectile dysfunction (ED). Experimental evidence showed that chronic treatment with sildenafil PDE5i in a mouse model of diet-induced obesity and insulin resistance improved insulin action and decreased circulating fatty acid levels. It has recently been shown that healthy athletes use PDE5i as performance enhancers, hence in the present study we investigated whether the long-lasting PDE5i tadalafil influences energy metabolism in C2C12 skeletal muscle cells by evaluating lacta...

Central serous chorioretinopathy following oral tadalafil

Eye — Fri, 04 Nov 2011 07:00:00 +0100

Authors: P Gordon-Bennett & T Rimmer (Source: Eye)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Focus on Phosphodiesterase Inhibitors for the Treatment of Erectile Dysfunction in Older Men.

Clinical Therapeutics — Sat, 29 Oct 2011 04:00:00 +0100

CONCLUSION: PDEIs are effective for erectile dysfunction and well tolerated in older men. PMID: 22036514 [PubMed - as supplied by publisher] (Source: Clinical Therapeutics)

Cialis to Treat Benign Prostatic Hyperplasia Approved by FDA

Disabled World — Thu, 13 Oct 2011 22:41:03 +0100

The U.S. Food and Drug Administration approves Cialis (tadalafil) to treat the signs and symptoms of benign prostatic hyperplasia (BPH), a condition in which the prostate gland becomes enlarged, and for the treatment of BPH and erectile dysfunction (ED), when the conditions occur simultaneously. Cialis was approved in 2003 for the treatment of ED. (Source: Disabled World)

CIALIS (Tadalafil) Tablet, Film Coated [Eli Lilly And Company]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 13 Oct 2011 05:00:00 +0100

Updated Date: Oct 13, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Phosphodiesterase Type 5 (PDE5) Inhibitors in Erectile Dysfunction: The Proper Drug for the Proper Patient

The Journal of Sexual Medicine — Thu, 13 Oct 2011 04:00:00 +0100

Conclusions. The simple algorithms prepared should be a useful tool to be used in daily practice, which may help in choosing the right treatment for each subject affected by ED. Corona G, Mondaini N, Ungar A, Razzoli E, Rossi A, and Fusco F. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: The proper drug for the proper patient. J Sex Med **;**:**–**. (Source: The Journal of Sexual Medicine)

Re: Tadalafil Administered Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A 1-Year, Open-Label Extension Study

The Journal of Urology — Thu, 13 Oct 2011 02:40:05 +0100

C. F. Donatucci, G. B. Brock, E. R. Goldfischer, P. J. Pommerville, A. Elion-Mboussa, J. D. Kissel and L. Viktrup Department of Surgery, Division of Urology, Duke University, Durham, North Carolina (Source: The Journal of Urology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

You Don't Have a "Sexpiration Date"

Psychology Today Sex Center — Sun, 09 Oct 2011 19:40:49 +0100

I just came a cross a blog by sexpert, Dr. Laura Berman where she was writing about older people and sex. It is no longer unusual to see people in their 50's, 60's, 70's, 80's and beyond being portrayed as sexy or sexually active in the media. Primary Topic: Sex read more (Source: Psychology Today Sex Center)

FDA approves tadalafil to treat benign prostatic hyperplasia

Drug Topics - Top News — Sun, 09 Oct 2011 04:00:00 +0100

FDA has approved tadalafil (Cialis, Eli Lilly) for 3 indications: ED, the signs and symptoms of BPH, and ED and the signs and symptoms of BPH in men who have both conditions. (Source: Drug Topics - Top News)

Cialis Gets FDA Green Light For Enlarged Prostate Treatment

Health News from Medical News Today — Sat, 08 Oct 2011 17:00:00 +0100

The FDA announced that it has approved Eli Lily's answer to Viagra, known as Cialis, for the treatment of enlarged prostate. This should prove to be a boon for Eli Lily's blockbuster impotence medication. The FDA stated that Cialis can now be labelled for treatment of a non cancerous enlarged prostate, (called benign prostatic hyperplasia (BPH) and be used for people who have both BPH and erectile dysfunction. Nearly half of men over fifty suffer from enlarged prostate problems that can cause difficulty urinating... (Source: Health News from Medical News Today)

FDA Approves Cialis To Treat Benign Prostatic Hyperplasia

Health News from Medical News Today — Sat, 08 Oct 2011 08:00:00 +0100

The U.S. Food and Drug Administration today approved Cialis (tadalafil) to treat the signs and symptoms of benign prostatic hyperplasia (BPH), a condition in which the prostate gland becomes enlarged, and for the treatment of BPH and erectile dysfunction (ED), when the conditions occur simultaneously. Cialis was approved in 2003 for the treatment of ED. Common symptoms of BPH include difficulty in starting urination and a weak urine stream; a sudden urge to urinate; and more frequent urination including at night... (Source: Health News from Medical News Today)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Cialis® For Once Daily Use Now FDA-Approved To Treat Men With Signs And Symptoms Of Benign Prostatic Hyperplasia (BPH) And Men With Both ED And BP

Health News from Medical News Today — Sat, 08 Oct 2011 08:00:00 +0100

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Cialis® (tadalafil) tablets for once daily use for the treatment of men who have both erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia (ED+BPH). The FDA also approved Cialis for once daily use for a separate indication for the treatment of the signs and symptoms of BPH. This means Cialis is now approved for three indications: ED, the signs and symptoms of BPH, and ED and the signs and symptoms of BPH in men who have both conditions... (Source: Health News from Medical News Today)

Cialis Approved to Treat Enlarged Prostate

Pharmacy News - Doctors Lounge — Fri, 07 Oct 2011 15:29:00 +0100

Also approved for treatment of BPH and erectile dysfunction occurring simultaneously (Source: Pharmacy News - Doctors Lounge)

FDA OKs Eli Lilly's Cialis for enlarged prostate

Reuters: Health — Fri, 07 Oct 2011 14:12:42 +0100

(Reuters) - U.S. drug regulators approved Eli Lilly's Cialis drug to treat enlargement of the prostate on Thursday, expanding use of the blockbuster impotence medicine. (Source: Reuters: Health)

FDA Approves Additional Use for Lilly's Cialis

Drugs.com - Pharma News — Fri, 07 Oct 2011 14:10:35 +0100

From Associated Press (October 6, 2011) SILVER SPRING, Md. -- The Food and Drug Administration said Thursday that it has approved Eli Lilly and Co.'s erectile dysfunction drug Cialis to be used in treating symptoms tied to a condition that leads... (Source: Drugs.com - Pharma News)

Cialis(R) for Once Daily Use Now FDA-Approved to Treat Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) and Men With Both Erectile Dysfunction (ED) and Signs and Symptoms of BPH

HSMN NewsFeed — Fri, 07 Oct 2011 12:46:09 +0100

Cialis for once daily use is the first and only medication approved to treat men with both ED and BPH INDIANAPOLIS, Oct. 7, 2011 (HSMN NewsFeed) -- Eli Lilly and Company (NYSE:LLY ) announced today that the U.S. Food and Drug Administration (FDA) has ... BiopharmaceuticalsEli Lilly, Cialis, tadalafil, erectile dysfunction, benign prostatic hyperplasia (Source: HSMN NewsFeed)

MedWorm Sponsor Message: Find the best January Sales in the UK.

FDA OKs Impotence Drug Cialis to Treat Enlarged Prostate

MedicineNet Senior Health General — Fri, 07 Oct 2011 07:00:00 +0100

Title: FDA OKs Impotence Drug Cialis to Treat Enlarged ProstateCategory: Health NewsCreated: 10/7/2011 10:05:00 AMLast Editorial Review: 10/7/2011 (Source: MedicineNet Senior Health General)

Minimal Clinically Important Differences in the Vaginal Insertion and Successful Intercourse Items of the Sexual Encounter Profile

The Journal of Sexual Medicine — Fri, 07 Oct 2011 04:00:00 +0100

Conclusions. The contextualization of treatment‐related changes into clinically relevant terms is essential to understanding treatment efficacy, interpreting results across studies, and for effective patient management. Overall, there was a better balance between sensitivity and specificity of the MCIDs using the ROC‐based approach for the SEP intercourse success item than for the vaginal insertion item. Araujo AB, Allen KR, Ni X, and Rosen RC. Minimal clinically important differences in the vaginal insertion and successful intercourse items of the Sexual Encounter Profile. J Sex Med **;**:**–**. (Source: The Journal of Sexual Medicine)

Tadalafil 2.5 or 5 mg Administered Once Daily for 12 Weeks in Men with Both Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia: Results of a Randomized, Placebo‐Controlled, Double‐Blind Study

The Journal of Sexual Medicine — Fri, 07 Oct 2011 04:00:00 +0100

Conclusions. Tadalafil 5 mg significantly improved both ED and BPH‐related outcomes through 12 weeks and was well tolerated. Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, Wong DG, and Secrest RJ. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: Results of a randomized, placebo‐controlled, double‐blind study. J Sex Med **;**:**–**. (Source: The Journal of Sexual Medicine)

FDA approves tadalafil to treat benign prostatic hyperplasia

Drug Topics - Clinical News — Fri, 07 Oct 2011 04:00:00 +0100

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Tadalafil (Cialis) approved in US to treat benign prostatic hyperplasia

NeLM - News — Fri, 07 Oct 2011 04:00:00 +0100

Source: FDA Area: News The FDA has approved tadalafil (Cialis) to treat the signs and symptoms of benign prostatic hyperplasia (BPH), and for the treatment of BPH and erectile dysfunction (ED), when the conditions occur simultaneously. (Source: NeLM - News)

FDA approves tadalafil to treat benign prostatic hyperplasia

Modern Medicine — Fri, 07 Oct 2011 04:00:00 +0100

US FDA OKs Cialis (tadalafil) for BPH

Modern Medicine — Fri, 07 Oct 2011 04:00:00 +0100

(Source: Modern Medicine)

Cialis Approved for Benign Prostatic Hyperplasia

Physician's First Watch current issue — Fri, 07 Oct 2011 04:00:00 +0100

(Source: Physician's First Watch current issue)

Cialis (Tadalafil) Approved For Benign Prostatic Hyperplasia Treatment, USA

Health News from Medical News Today — Fri, 07 Oct 2011 03:00:00 +0100

Tadalafil (Cialis) has been approved by the FDA (Food and Drug Administration) for the treatment of BPH (benign prostatic hyperplasia) signs and symptoms - a condition in which the prostate gland enlarges. It has also been approved for the treatment of simultaneous BPH and ED (erectile dysfunction). Since 2003, the medication has been on the market legally in the USA for ED treatment... (Source: Health News from Medical News Today)

MedWorm Sponsor Message: Find the best January Sales in the UK.

FDA OKs Impotence Drug Cialis to Treat Enlarged Prostate

The Doctors Lounge - Urology — Fri, 07 Oct 2011 00:41:23 +0100

Pill may be especially beneficial for men battling both conditions, agency says (Source: The Doctors Lounge - Urology)

FDA Approves Cialis to Treat Benign Prostatic Hyperplasia

Drugs.com - New Drug Approvals — Fri, 07 Oct 2011 00:10:13 +0100

October 6, 2011 -- The U.S. Food and Drug Administration today approved Cialis (tadalafil) to treat the signs and symptoms of benign prostatic hyperplasia (BPH), a condition in which the prostate gland becomes enlarged, and for the treatment of BPH... (Source: Drugs.com - New Drug Approvals)

FDA Approves Cialis to Treat Enlarged Prostate

WebMD Health — Fri, 07 Oct 2011 00:02:02 +0100

Cialis has been approved by the FDA for the treatment of enlarged prostate. (Source: WebMD Health)

FDA Okays ED Drug for Enlarged Prostate

MedPage Today State Required CME — Thu, 06 Oct 2011 23:43:10 +0100

(MedPage Today) -- Tadalafil (Cialis), currently marketed for erectile dysfunction, also may be used to treat benign prostatic hyperplasia, the FDA said. (Source: MedPage Today State Required CME)

Tadalafil Approved for Benign Prostatic HyperplasiaTadalafil Approved for Benign Prostatic Hyperplasia

Medscape Today Headlines — Thu, 06 Oct 2011 23:11:22 +0100

The FDA also has approved the drug for treating both BPH and erectile dysfunction when the conditions occur together. Medscape Medical News (Source: Medscape Today Headlines)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

FDA approves Cialis to treat benign prostatic hyperplasia

Food and Drug Administration — Thu, 06 Oct 2011 20:12:00 +0100

FDA Approves Cialis to Treat Enlarged Prostate

WebMD Health — Thu, 06 Oct 2011 05:00:00 +0100

Cialis has been approved by the FDA for the treatment of enlarged prostate. (Source: WebMD Health)

10‐Year Analysis of Adverse Event Reports to the Food and Drug Administration for Phosphodiesterase Type‐5 Inhibitors

The Journal of Sexual Medicine — Sat, 01 Oct 2011 04:00:00 +0100

Conclusion. Reports of deaths associated with PDE5‐i remain around 5% of total reported events. Despite inherent limitations from evaluating FDA reports of AEs, it is important that these reports be reviewed outside pharmaceutical industry support in order to provide due diligence and transparency. Lowe G and Costabile RA. 10‐year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type‐5 inhibitors. J Sex Med **;**:**–**. (Source: The Journal of Sexual Medicine)

Re: Endothelial Apoptosis Decrease Following Tadalafil Administration in Patients With Arterial ED Does Not Last After Its Discontinuation

The Journal of Urology — Wed, 28 Sep 2011 04:00:00 +0100

S. La Vignera, R. A. Condorelli, E. Vicari, R. D'Agata and A. E. Calogero Section of Endocrinology, Andrology and Internal Medicine, Department of Internal Medicine and Systemic Diseases, University of Catania, Catania, Italy (Source: The Journal of Urology)

Re: A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Once-a-Day Tadalafil in Men With Erectile Dysfunction who are Naïve to PDE5 Inhibitors

The Journal of Urology — Wed, 28 Sep 2011 04:00:00 +0100

F. Montorsi, A. Aversa, I. Moncada, P. Perimenis, H. Porst, C. Barker, M. A. Shane and S. Sorsaburu Department of Urology, Scientific Institute Hospital San Raffaele, Milan, Italy (Source: The Journal of Urology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

PDE5 inhibitors: targeting erectile dysfunction in diabetics.

Current Opinion in Pharmacology — Thu, 15 Sep 2011 04:00:00 +0100

Authors: Francis SH, Corbin JD Abstract Erectile dysfunction (ED) is strongly linked to cardiovascular disease (CVD), especially in diabetics. ED is associated with deleterious changes in the overall vasculature and is recognized as an indicator of higher risk for adverse cardiovascular events. Endothelial dysfunction, vascular smooth muscle changes and increased fibrosis are indicated as major players in both ED and CVD. ED in diabetics is more refractory to acute treatment with phosphodiesterase-5 (PDE5) inhibitors (Viagra, Cialis, Levitra, Zydena) than in non-diabetics, but recent studies indicate that chronic administration of these drugs improves endothelial function, preserves vascular smooth muscle and decreases fibrotic changes. Use of PDE5 inhibitors in pre-diabetic and di...

Sexually transmitted infection in HIV-positive men with erectile dysfunction using phosphodiesterase-5 inhibitors

Sexually Transmitted Infections — Tue, 13 Sep 2011 04:00:00 +0100

HIV-positive men are commonly prescribed phosphodiesterase-5 (PDE5) inhibitors for erectile dysfunction (ED). When prescribing, consideration should be given to possible onward transmission of HIV, which is enhanced by the presence of other sexually transmitted infections (STIs).1–3 We were unable to find any reports of STI acquisition in men with HIV using PDE5 inhibitors. The aim was to audit the management of ED within our HIV cohort in Belfast according to British Society of Sexual Medicine guidelines.4 Documentation of STI diagnoses and safer sex discussion was also reviewed in those who had received PDE5 inhibitors (sildenafil, tadalafil and vardenafil) between 2002 and 2010. Data were obtained from case notes and pharmacy records. Fifty HIV-positive men received PDE5 inhibitor...

Preparation of Imprinted Polymers at Surface of Magnetic Nanoparticles for the Selective Extraction of Tadalafil from Medicines

ACS Applied Materials and Interfaces — Wed, 07 Sep 2011 15:43:27 +0100

ACS Applied Materials & InterfacesDOI: 10.1021/am2007855 (Source: ACS Applied Materials and Interfaces)

Clinical Efficacy of Phosphodiesterase‐5 Inhibitor Tadalafil in Eisenmenger Syndrome—A Randomized, Placebo‐controlled, Double‐blind Crossover Study

Congenital Heart Disease — Thu, 01 Sep 2011 04:00:00 +0100

Conclusion. In this first short‐term placebo‐controlled trial of tadalafil in patients of ES, the drug was well tolerated and significantly improved exercise capacity, functional class, SO2, and pulmonary hemodynamics.http://www.clinicaltrial.gov/ct2/show/NCT01200732?term=NCT01200732&rank=1 (Source: Congenital Heart Disease)

A Man With Transient Dyspnea After Taking Tadalafil

Consultant Live — Wed, 31 Aug 2011 12:00:00 +0100

A 26-year-old man presented with sudden onset of palpitations and shortness of breath after incidentally taking tadalafil. He had no other symptoms and no history of illnesses during childhood. He drank socially but denied smoking and use of illicit drugs. (Source: Consultant Live)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Factors associated with ejaculatory and orgasmic dysfunction in men with erectile dysfunction: analysis of clinical trials involving the phosphodiesterase type 5 inhibitor tadalafil

BJU International — Mon, 22 Aug 2011 23:00:00 +0100

CONCLUSIONS• EjD and OD occurred at baseline in more than one in three men enrolled in tadalafil trials. Even men with mild ED reported EjD or OD.• Further studies are warranted to better understand the impacts of EjD and OD on male sexuality and quality of life. (Source: BJU International)

What Is Cialis? What Is Tadalafil?

Health News from Medical News Today — Thu, 18 Aug 2011 08:00:00 +0100

Tadalafil, known under the brand name Cialis for the treatment of erectile dysfunction and Adcirca for pulmonary arterial hypertension, is a PDE5 inhibitor. Its main competitors are sildenafil citrate (Viagra) and vardenafil (Levitra). Tadalafil's chemical formula is C22H19N3O4. Cialis became nicknamed "the weekend pill" because its effects last 36 hours. Viagra and Levitra are effective for up to 8 hours... (Source: Health News from Medical News Today)

Tadalafil rehabilitation therapy preserves penile size after bilateral nerve sparing radical retropubic prostatectomy

International Braz J Urol — Thu, 11 Aug 2011 15:21:53 +0100

CONCLUSION: Although further large sampled trials are needed to describe the possible positive effect of tadalafil or other PDE5-I's on penile size after BNSRRP, tadalafil rehabilitation is effective in preserving penile size especially in the early postoperative period after BNSRRP. (Source: International Braz J Urol)

Impurity fingerprints for the identification of counterfeit medicines-A feasibility study.

Analytica Chimica Acta — Thu, 04 Aug 2011 07:30:21 +0100

In this study, impurity profiles were treated like fingerprints representing the quality of the samples. A total of 73 samples of counterfeit and imitations of Viagra(®) and 44 samples of counterfeit and imitations of Cialis(®) were analysed on a HPLC-UV system. A clear distinction has been obtained between genuine and illegal tablets by the mean of a discriminant partial least squares analysis of the log transformed chromatograms. Following exploratory analysis of the data, two classification algorithms were applied and compared. In our study, the k-nearest neighbour classifier offered the best performance in terms of correct classification rate obtained with cross-validation and during external validation. For Viagra(®), both cross-validation and external validation sets returned a 10...

Capsule shells adulterated with tadalafil

Forensic Science International — Wed, 03 Aug 2011 04:00:00 +0100

Abstract: Following a health complaint a food supplement was brought in for analysis on the suspicion of being adulterated with a synthetic drug substance. When the capsule content did not show evidence of adulteration, the capsule shell was investigated. Using HPLC-DAD and HPLC–MS the capsule shell was found to contain 2.85mg of the erectile dysfunction drug tadalafil. Using microscopy and RAMAN spectroscopy the presence of tadalafil was shown throughout the gelatine matrix as particles and dissolved into the matrix. The adulteration is probably carried out by adding tadalafil powder to a gelatine jelly in the manufacturing of the capsules shells. Because this technique may also be used for other drug substances, capsules shells should be considered a vehicle for hiding drug substances ...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Phosphodiesterase Type 5 Expression in Human and Rat Lower Urinary Tract Tissues and the Effect of Tadalafil on Prostate Gland Oxygenation in Spontaneously Hypertensive Rats

The Journal of Sexual Medicine — Tue, 02 Aug 2011 23:00:00 +0100

Conclusion. Human vesicular‐deferential artery is characterized by a high expression and activity of PDE5, which was inhibited by tadalafil in vitro. In SHR, tadalafil increases prostate tissue oxygenation, thus suggesting a possible mechanism through which PDE5i exert beneficial effects on LUT symptoms. Morelli A, Sarchielli E, Comeglio P, Filippi S, Mancina R, Gacci M, Vignozzi L, Carini M, Vannelli GB, and Maggi M. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med **;**:**–**. (Source: The Journal of Sexual Medicine)

The Controversial Role of Phosphodiesterase Type 5 Inhibitors in the Treatment of Premature Ejaculation

The Journal of Sexual Medicine — Wed, 27 Jul 2011 19:25:08 +0100

Conclusions. While it is evident that PDE5is are the first choice in patients with comorbid ED and PE (where one may be secondary to the other), well‐designed studies on the possible use of PDE5is in PE patients without ED are still limited. The issue will be less controversial when further evidence on the role of NO and PDE5 in the mechanism of ejaculation is available. Jannini EA, McMahon C, Chen J, Aversa A, and Perelman M. The controversial role of PDE5 inhibitors in the treatment of premature ejaculation. J Sex Med 2011;8:2135–2143. (Source: The Journal of Sexual Medicine)

Dysfunction of the endothelial‐platelet pathway in patients with erectile dysfunction before and after daily treatment with tadalafil

Andrologia — Sun, 24 Jul 2011 23:00:00 +0100

This study included 50 patients with arterial ED. EMPa and VR levels were measured by using flow cytometry. The CD45neg‐CD144pos‐annexin VPos events were defined as EMPa, and the CD51pos–CD61pos events were defined as VR. Patients with ED were evaluated before and after daily treatment with 5 mg tadalafil for 90 days. Patients with arterial ED had serum concentrations of EMPa and VR significantly higher than the control group at baseline. After tadalafil, the serum concentrations of EMPa and VR of the patients with arterial ED were significantly lower than before treatment, but significantly higher than controls. Patients with arterial ED expressed higher levels of both EMPa that are associated with dysfunction of the arterial endothelial pathway and VR‐expressing platelet‐en...

Are Phosphodiesterase Type 5 Inhibitors Associated with Vision‐Threatening Adverse Events? A Critical Analysis and Review of the Literature

The Journal of Sexual Medicine — Mon, 18 Jul 2011 23:00:00 +0100

Conclusion. There is lack of conclusive evidence to indicate a direct cause–effect relationship between PDE5 inhibitor use and vision‐threatening ocular events. Men who use PDE5 inhibitors appear to suffer vision‐threatening complications at the same frequency as the general population. However, minor visual adverse effects occur in 3–11% of users and they are transient and reversible. Azzouni F and Abu samra K. Are phosphodiesterase type 5 inhibitors associated with vision‐threatening adverse events? A critical analysis and review of the literature. J Sex Med **;**:**–**. (Source: The Journal of Sexual Medicine)

Effects of chronic tadalafil use on the testes and sperm parameters of old albino rats

Andrologia — Sun, 17 Jul 2011 23:00:00 +0100

This study aimed at exploring whether the chronic use of tadalafil has an adverse effect on the testes and semen of old albino rats. Sixty male albino rats were divided into three groups. Group 1: given 2 ml saline orally for 90 days. Group 2: received tadalafil orally (1.8 mg kg−1 day−1 for 3 months equivalent to 20 mg day−1 for 3 months as in human dose) and Group 3: received tadalafil orally (1.8 mg kg−1 day−1 for 6 months equivalent to 20 mg day−1 for 6 months as in human dose). Animals were observed daily for signs of toxicity and mortality. Body weight and food consumption were recorded once a week. After sacrificing the animals, gross examination of the testes was performed in situ and then the epididymis was processed for the evaluation o...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Tadalafil: A Long-Acting Phosphodiesterase-5 Inhibitor for the Treatment of Pulmonary Arterial Hypertension.

Clinical Therapeutics — Tue, 12 Jul 2011 23:00:00 +0100

CONCLUSIONS: In the small number of studies available, tadalafil was effective and well tolerated when used to treat patients with PAH. Compared with placebo, tadalafil was associated with significant improvements in exercise capacity and reduced time to clinical worsening (68% relative risk reduction; P = 0.038). There is limited evidence comparing tadalafil with sildenafil and vardenafil, and the studies are limited by short treatment durations. PMID: 21762988 [PubMed - as supplied by publisher] (Source: Clinical Therapeutics)

Identify drug repurposing candidates by mining the Protein Data Bank.

Briefings in Bioinformatics — Thu, 30 Jun 2011 23:00:00 +0100

Authors: Moriaud F, Richard SB, Adcock SA, Chanas-Martin L, Surgand JS, Ben Jelloul M, Delfaud F Predicting off-targets by computational methods is gaining increasing interest in early-stage drug discovery. Here, we present a computational method based on full 3D comparisons of 3D structures. When a similar binding site is detected in the Protein Data Bank (PDB) (or any protein structure database), it is possible that the corresponding ligand also binds to that similar site. On one hand, this target hopping case is probably rare because it requires a high similarity between the binding sites. On the other hand, it could be a strong rational evidence to highlight possible off-target reactions and possibly a potential undesired side effect. This target-based drug repurposing can be exten...

ADCIRCA (Tadalafil) Tablet [United Therapeutics Corporation]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 30 Jun 2011 05:00:00 +0100

Updated Date: Jun 30, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Erectile dysfunction

Clinical Evidence — Wed, 29 Jun 2011 19:28:22 +0100

New option(s) added for: Tadalafil in men with cardiovascular disease New option added. Categorised as Unknown effectiveness, as we found no RCT evidence to assess the effects of this intervention. Vardenafil in men with cardiovascular disease New option added. Categorised as Unknown effectiveness, as we found no RCT evidence to assess the effects of this intervention. Tadalafil in men with spinal cord injury New option added. Categorised as Likely to be beneficial. Vardenafil in men with spinal cord injury New option added. Categorised as Unknown effectiveness, as we found no RCT evidence to assess the effects of this intervention Tadalafil in men with prostate cancer or undergoing prostatect...

Subarachnoid hemorrhage associated with tadalafil.

American Journal of Health-System Pharmacy : AJHP — Mon, 27 Jun 2011 12:46:07 +0100

Authors: Sheikh-Taha M, Alaywa RA PMID: 21690423 [PubMed - in process] (Source: American Journal of Health-System Pharmacy : AJHP)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Counterfeit Cialis Seized in the Greater Toronto Area

Government of Canada News - Health Canada — Tue, 21 Jun 2011 20:45:00 +0100

Following an R.C.M.P. seizure of counterfeit Cialis in the Greater Toronto Area, Health Canada is reminding Canadians that unauthorized and counterfeit health products can pose serious risks to their health as they have not been reviewed by the Department for safety, quality, or efficacy (Source: Government of Canada News - Health Canada)

What's with the infinitely irritating Cialis bathtubs?

Psychology Today Sex Center — Tue, 21 Jun 2011 02:43:25 +0100

I apologize in advance. But I can't take it anymore. I freely admit this is not at all a timely posting. I'm just hoping to get my intense aggravation with the Cialis bathtubs finally out of my system. I hoped it would go away. But it hasn't, and now I hope this post will do the trick. So here goes (better late than never): What's with the bathtubs?Editorial Controls Editorial Status: No Status read more (Source: Psychology Today Sex Center)

CIALIS (Tadalafil) Tablet, Film Coated [Eli Lilly And Company]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 17 Jun 2011 05:00:00 +0100

Updated Date: Jun 17, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Clinical management of erectile dysfunction

International Journal of Urological Nursing — Thu, 16 Jun 2011 16:34:23 +0100

Erectile dysfunction (ED) affects 8% of 40‐year‐old men, increasing to 40% in 60‐year‐old men. It can be the first presentation of vascular disease and the average time between onset of ED and the first coronary vascular event is 3 years. The prevalence of ED is increasing and will continue to increase as the population ages. Prostate surgery commonly causes ED and nurses need to identify men with ED early, as treatment for ED should be commenced at the earliest opportunity provided the man and his partner want to engage in sexual activity. Options for treatment include phosphodiesterase type 5 inhibitors (sildenafil, tadalafil or vardenafil) as required, or ‘once daily’ for tadalafil. Alternative options include urethral pellets, intracavernosal injections, vacuum devices, cou...

Endothelial apoptosis decrease following tadalafil administration in patients with arterial ED does not last after its discontinuation

International Journal of Impotence Research — Wed, 15 Jun 2011 23:00:00 +0100

Authors: S La Vignera, R A Condorelli, E Vicari, R D'Agata & A E Calogero (Source: International Journal of Impotence Research)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Tadalafil alters of energy metabolism in C2C12 skeletal muscle cells.

Acta Biochim Pol — Wed, 15 Jun 2011 23:00:00 +0100

Authors: Sabatini S, Sgrò P, Duranti G, Ceci R, Di Luigi L Phosphodiesterases (PDEs) are a family of enzymes that hydrolyze cyclic nucleotides, thereby modulating cell functions. Three highly selective PDE5 inhibitors (PDE5i), sildenafil, vardenafil and tadalafil, have been developed for treatment of erectile dysfunction (ED). Experimental evidence showed that chronic treatment with sildenafil PDE5i in a mouse model of diet-induced obesity and insulin resistance improved insulin action and decreased circulating fatty acid levels. It has recently been shown that healthy athletes use PDE5i as performance enhancers, hence in the present study we investigated whether the long-lasting PDE5i tadalafil influences energy metabolism in C2C12 skeletal muscle cells by evaluating lactate producti...

Effect of tadalafil in chronic renal failure rabbits: relevance to erectile dysfunction.

J Zhejiang Univ Sci ... — Tue, 31 May 2011 23:00:00 +0100

Authors: Zhang MY, Fu Q, Bian W It is of great importance to investigate an effective and reliable medication against chronic renal failure (CRF)-related erectile dysfunction (ED), which aims to improve patients' life qualities. The concentrations of cyclic guanosine monophosphate (cGMP) in the corpus cavernosal smooth muscle of both CRF and control rabbits were measured. The effects of various concentrations of tadalafil, papaverine, and sodium nitroprusside on the relaxation responses of corpus cavernosal smooth muscle pre-contracted with phenylephrine in CRF rabbits were observed. There was significant difference in the concentration of cGMP between CRF and control rabbits (P<0.01). Tadalafil had the greatest impacts on CRF rabbits when given the same concentration of papaverine ...

A Randomized, Double‐Blind, Placebo‐Controlled, Parallel Study to Assess the Efficacy and Safety of Once‐A‐Day Tadalafil in Men with Erectile Dysfunction Who Are Naïve to PDE5 Inhibitors

The Journal of Sexual Medicine — Tue, 31 May 2011 23:00:00 +0100

Conclusions. In PDE5 inhibitor‐naïve men, tadalafil once a day significantly improved EF compared with placebo. Safety results were consistent with previous tadalafil once‐a‐day clinical trials. Montorsi F, Aversa A, Moncada I, Perimenis P, Porst H, Barker C, Shane MA, and Sorsaburu S. A randomized, double‐blind, placebo‐controlled, parallel study to assess the efficacy and safety of once‐a‐day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors. J Sex Med **;**:**–**. (Source: The Journal of Sexual Medicine)

Current pharmacotherapy of lower urinary tract symptoms

Surgery (Medicine Publishing) — Thu, 19 May 2011 16:41:16 +0100

Abstract: Lower urinary symptoms (LUTS), including the overactive bladder (OAB) syndrome, can be found in 10–15% of all men and women and have often major effects on quality of life and social functioning. The first line of pharmacological treatment of OAB in women has been and still is antimuscarinic drugs. In men α1-adrenoceptor (AR) antagonists remain the standard treatment of LUTS. However, recent advances in the physiology/pathophysiology of LUTS/OAB, recognizing the functional contribution of the urothelium, the spontaneous myocyte activity during bladder filling, and the diversity of nerve transmitters involved, have sparked interest in novel possibilities to treat these conditions. For example, new, selective α1-AR antagonists (naftopidil, silodosin), β3-AR agonists (mirabegro...

Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: A prospective randomized study

International Journal of Urology — Tue, 17 May 2011 23:00:00 +0100

Conclusions: In patients suffering from ED and storage symptoms after surgical treatment for LUTS‐BPE, tadalafil 5 mg given once daily for 12 weeks provided a comparable improvement in IPSS to solifenacin 5 mg given for the same period of time. (Source: International Journal of Urology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding.

Cellular Signalling — Mon, 16 May 2011 23:00:00 +0100

Authors: Corbin JD, Francis SH Phosphodiesterase-5 (PDE5) is a dimer containing a cGMP-specific catalytic domain and an allosteric cGMP-binding subdomain (GAF A) on each subunit. PDE5 exhibits three conformational forms that can be separated by Native PAGE and are denoted as Bands 1, 2, and 3 in decreasing order of mobility. A preparation comprised mainly of Band 2 PDE5 was partially converted to Band 3 PDE5 by 1h incubation with cGMP or the PDE5-specific inhibitors sildenafil, vardenafil, or tadalafil, but not with cAMP, milrinone (PDE3-specific), or rolipram (PDE4-specific). Band 2 PDE5 was converted almost entirely to Band 3 PDE5 by overnight incubation with sildenafil at 30°C. This time-dependent conversion was accompanied by a 7-fold increase in allosteric cGMP-binding activity, ...

Oral Tadalafil Administration Plus Low Dose Vasodilator Injection: A Novel Approach to Erection Induction for Penile Color Duplex Ultrasound

The Journal of Urology — Sun, 15 May 2011 23:00:00 +0100

Conclusions: Oral tadalafil plus low dose vasodilator led to a significantly better clinical response than high dose vasodilator. Penile color duplex ultrasound parameters showed no difference between the 2 modes. Thus, this mixed mode emerges as a possible alternative to high dose vasodilator injection. (Source: The Journal of Urology)

Tadalafil analgesia in experimental arthritis involves suppression of intra‐articular TNF release

British Journal of Pharmacology — Sun, 08 May 2011 23:00:00 +0100

Conclusions and implications: Therapeutic oral administration of tadalafil provides analgesia mediated by a guanylyl cyclase mechanism that is independent of endogenous opioids release. This effect of tadalafil is associated to a decrease in neutrophil influx and TNF release into inflamed joints. (Source: British Journal of Pharmacology)

SMC does not recommend tadalafil (Adcirca ®) for use within NHS Scotland due to non-submission

NeLM - Drug Specific Reviews — Sun, 08 May 2011 23:00:00 +0100

Source: Scottish Medicines Consortium (SMC) Area: Evidence > Drug Specific Reviews The Scottish Medicines Consortium (SMC) has not recommended tadalafil (Adcirca ®) for use within NHS Scotland for the treatment of pulmonary arterial hypertension, classified as WHO functional class II and III, to improve exercise capacity, due to non-submission from the holder of the marketing authorisation. (Source: NeLM - Drug Specific Reviews)

Effects of phosphodiesterase type 5 inhibitors on endothelial function and cardiovascular autonomic nerve function in men

Journal of Men's Health — Sat, 30 Apr 2011 23:00:00 +0100

This article discusses current use, safety profile and future therapeutic developments of this class of dugs. (Source: Journal of Men's Health)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Survey Conducted by AskTheDoctor.com Says Cialis is Dangerous and Has Too Many Side Effects; Will be Recommending FDA Remove Drugs From Shelves

Medical News (via PRIMEZONE) — Sun, 24 Apr 2011 20:05:00 +0100

NEW YORK, April 24, 2011 (GLOBE NEWSWIRE) -- In a recent survey conducted with over 30 physicians from popular health website AskTheDoctor.com, 30 out of the 30 physicians recommended that men suffering from erectile dysfunction are better off taking viagra than cialis. 29 out of those 30 physicians refuse to even prescribe cialis to their patients due to harmful side effects they have noticed. (Source: Medical News (via PRIMEZONE))

Reyataz 150mg, 200mg and 300mg Hard Capsules (atazanavir sulphate) - Revised SPC

NeLM - SPC Changes — Sun, 17 Apr 2011 23:00:00 +0100

Source: eMC (electronic Medicines Compendium) Area: Other Library Updates > SPC Changes The following information has been added to section 4.3 of the SPC for Reyataz Hard Capsules: The PDE5 inhibitor sildenafil is contraindicated when used for the treatment of pulmonary arterial hypertension (PAH) only (see section 4.5). For co-administration of sildenafil for the treatment of erectile dysfunction see section 4.4 and section 4.5. The following has been added to section 4.4 PDE5 inhibitors used for the treatment of erectile dysfunction: particular caution should be used when prescribing PDE5-inhibitors (sildenafil, tadalafil, or vardenafil) for the treatment of erectile dysfunction in patients receiving REYATAZ with concomitant low-dose ritonavir. Co-admini...

As Generics Near, Makers Tweak Erectile Drugs

NYT — Thu, 14 Apr 2011 04:30:16 +0100

The multibillion-dollar market is being driven by novel applications to compete with coming generics. (Source: NYT)

New study - You can literally spice up your love life with spices

NaturalNews.com — Sat, 09 Apr 2011 07:00:00 +0100

(NaturalNews) (NaturalNews) Drugs for pumping up sex lives come with a long list of potentially bothersome and even dangerous side effects. But scientists from the University of Guelph have come up with evidence natural aphrodisiacs exist. In fact, if you want to spice up your sex life, try doing it literally -- with spices.Specifically, ginseng and saffron added to the diet are proven sexual performance boosters, according to the researchers' new scientific review of hundreds of studies of natural aphrodisiacs. Yohimbine, a natural chemical from yohimbe trees in West Africa, was also found to improve human sexual function.People reported increased sexual desire after eating muira puama, a flowering plant found in Brazil, and maca root, a mustard plant grown in the Andes, too. Despite its ...

MedWorm Sponsor Message: Find the best January Sales in the UK.

CIALIS (Tadalafil) Tablet, Film Coated [Eli Lilly And Company]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 08 Apr 2011 05:00:00 +0100

Updated Date: Apr 8, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Role of a Novel Tetrodotoxin‐Resistant Sodium Channel in the Nitrergic Relaxation of Corpus Cavernosum from the South American Rattlesnake Crotalus Durissus Terrificus

The Journal of Sexual Medicine — Wed, 06 Apr 2011 23:00:00 +0100

Conclusions. Rattlesnake CC relaxation is mediated by the NO‐cGMP‐PDE5 pathway in a manner similar to mammals. The novel TTX‐resistant Na channel identified here may be responsible for the slow response of smooth muscle following nerve stimulation and could explain the extraordinary duration of snake coitus. Capel RO, Mónica FZ, Porto M, Barillas S, Muscará MN, Teixeira SA, Arruda AMM, Pissinatti, L, Pissinatti A, Schenka AA, Antunes E, Nahoum C, Cogo JC, de Oliveira MA, and De Nucci G. Role of a novel tetrodotoxin‐resistant sodium channel in the nitrergic relaxation of corpus cavernosum from the South American rattlesnake Crotalus durissus terrificus. J Sex Med **;**:**–**. (Source: The Journal of Sexual Medicine)

PPMD's Senior Director of Research Sharon Hesterlee recaps the latest Health Research Alliance (HRA) and MDA meetings in her blog.community.parentprojectmd.org

Parent Project Muscular Dystrophy — Wed, 06 Apr 2011 23:00:00 +0100

Out and About Posted by Sharon Hesterlee on April 7, 2011 at 2:24pm Send Message View Sharon Hesterlee's blog I’ve just spent two weeks in a row on the road at different meetings—first the Health Research Alliance (HRA) meeting in New York and then the Muscular Dystrophy Association meeting in Las Vegas. HRA is an organization made up of most of the major non-profit funders of health research -- the members meetings are designed to keep us up to date on the latest trends in research and funding and to allow us to learn from one another. I chair the HRA Working Group on “Funders of Drug and Other Therapeutics Development” which met over breakfast in New York. For this working group meeting we invited three industry gue...

Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis

NeLM - Drug Class Focused Reviews — Mon, 04 Apr 2011 23:00:00 +0100

Source: DARE Area: Evidence > Drug Class Focused Reviews CRD Summary: This generally well-conducted review concluded that oral PDE-5 inhibitors improved erectile function and had similar efficacy and safety profiles; the efficacy and value of hormone treatments remained uncertain. Despite some limitations, the review included a large number of studies and the direction of effect seemed to be consistent across studies and analyses. The conclusions are likely to be reliable. [ Included studies evaluated sildenafil, vardenafil, tadalafil, mirodenafil, udenafil and hormonal treatments (oral, intramuscular, gel, cream or patch testosterone); drug regimens varied across studies. ] CRD Commentary: The authors addressed a clear research question with appropriate inclusion criteria. Several so...

Ritonavir/tadalafil interaction: First report of an interaction, leading to priapism: case report

Reactions — Mon, 04 Apr 2011 16:58:12 +0100

(Source: Reactions)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Adcirca (Tadalafil Tablets) - updated on RxList

RxList - New and Updated Drug Monographs — Mon, 04 Apr 2011 07:00:00 +0100

Adcirca (Tadalafil Tablets) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)

Prevalence and medical management of erectile dysfunction in Asia.

Asian Journal of Andrology — Sun, 03 Apr 2011 23:00:00 +0100

Authors: Park K, Hwang EC, Kim SO Erectile dysfunction (ED) is an important worldwide health issue that has a significant negative impact on the quality of life and life satisfaction of both the affected individual and his partner. Here we review the prevalence of ED in Asia, associated factors that may influence sexual attitudes and sexual behaviours, and randomized clinical trials (RCTs) of phosphodiesterase-5 (PDE-5) inhibitors to evaluate the clinical efficacy and safety of PDE-5 inhibitors in Asian men. We searched for English-language articles in MEDLINE and PubMed from January 2000 to September 2010. Our results showed that the overall reported prevalence rate of ED in Asia ranged widely, from 2% to 88%. This finding indicates that ED is a common and major health problem in this...

X-Hero and Male Enhancer: Recall - Undeclared Drug Ingredient

FDA MedWatch — Tue, 29 Mar 2011 14:25:00 +0100

Products marketed as dietary supplement contain drug ingredients sulfosildenafil or tadalafil, which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels. (Source: FDA MedWatch)

Tadalafil: First report of Leber's hereditary optic atrophy: case report

Reactions — Sun, 13 Mar 2011 17:03:03 +0100

(Source: Reactions)

Vardenafil in Pulmonary Arterial Hypertension: A Randomized, Double-blind, Placebo-controlled Study.

American Journal of Respiratory and Critical Care Medicine — Fri, 11 Mar 2011 00:00:00 +0100

CONCLUSIONS: Vardenafil is effective and well tolerated in patients with PAH at a dose of 5 mg twice daily. Clinical trials information available at www.clinicaltrials.gov, identifier code NCT00718952. PMID: 21471085 [PubMed - as supplied by publisher] (Source: American Journal of Respiratory and Critical Care Medicine)

MedWorm Sponsor Message: Find the best January Sales in the UK.

ADCIRCA (Tadalafil) Tablet [United Therapeutics Corporation]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 08 Mar 2011 05:00:00 +0100

Updated Date: Mar 8, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

CIALIS (Tadalafil) Tablet, Film Coated [Eli Lilly And Company]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 02 Mar 2011 05:00:00 +0100

Updated Date: Mar 2, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

ADCIRCA (Tadalafil) Tablet [United Therapeutics Corporation]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 02 Mar 2011 05:00:00 +0100

Updated Date: Mar 2, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

335 the assessment of tadalafil effect on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in patients treated with standard medication

European Urology Supplements — Tue, 01 Mar 2011 00:00:00 +0100

(Source: European Urology Supplements)

336 tadalafil 5 mg once daily improves erectile dysfunction (ed) and the signs and symptoms of benign prostatic hyperplasia (bph-luts) in men with both ed and bph-luts: results of a randomized, double-blind, placebo-controlled, multinational study

European Urology Supplements — Tue, 01 Mar 2011 00:00:00 +0100

(Source: European Urology Supplements)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

1023 tadalafil once daily and extracorporeal shock wave therapy in the management of patients with peyronie's disease and erectile dysfunction. results from a prospective randomized trial

European Urology Supplements — Tue, 01 Mar 2011 00:00:00 +0100

(Source: European Urology Supplements)

Counterfeit erectile dysfunction drugs: update from MHRA on seizures and prosecution

NeLM - News — Fri, 25 Feb 2011 00:00:00 +0100

Source: MHRA Area: News In 2010, UK Border Agency (UKBA) officers seized over 8.5 million fake and unlicensed Viagra tablets, worth around £13 million, before they could enter the black market. The Agency refers seized pharmaceutical drugs to the MHRA who then look to take criminal enforcement action against those attempting to trade the tablets on the black market. In a related story, a gang who planned to make half a million counterfeit tadalafil tablets with a street value of £1.6 million from a residential flat in central London has been jailed at the Old Bailey, following a City of London Police investigation. (Source: NeLM - News)

Extenze Tablets: Recall

FDA MedWatch — Wed, 23 Feb 2011 19:54:00 +0100

Counterfeit dietary supplement contains tadalafil, sildenafil, and/or sibutramine, which may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke. (Source: FDA MedWatch)

ADCIRCA (Tadalafil) Tablet [United Therapeutics Corporation]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 22 Feb 2011 05:00:00 +0100

Updated Date: Feb 22, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction

Clinics — Sat, 19 Feb 2011 18:48:05 +0100

OBJECTIVES: To investigate the acute effect of phosphodiesterase type 5 (PDE5) inhibitor on erectile dysfunction by evaluating serum oxidative status and prolidase activity. METHODS: Serum samples of 36 patients with erectile dysfunction and 30 control cases were analyzed for total antioxidant status, total oxidant status, and prolidase activity, before and after the administration of tadalafil citrate. RESULTS: Before and after tadalafil citrate administration, serum total antioxidant status, total oxidant status, and prolidase were 1.1+0.0 vs. 1.6 + 0.0 umol H2O2 Eq/L, 10.3+1.1 vs. 6.9 + 1.2 umol H2O2 Eq/L, and 236.4+19.5 vs. 228.2 + 19.2 U/L, respectively (p

The Role of PDE5 Inhibitors in Penile Septal Scar Remodeling: Assessment of Clinical and Radiological Outcomes

The Journal of Sexual Medicine — Wed, 16 Feb 2011 00:00:00 +0100

Conclusion. Low‐dose daily tadalafil is a safe and effective treatment option in septal scar remodeling. Chung E, DeYoung L, and Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: Assessment of clinical and radiological outcomes. J Sex Med **;**:**–**. (Source: The Journal of Sexual Medicine)

Efficacy and Tolerability of Tadalafil for Treatment of Erectile Dysfunction in Men Taking Serotonin Reuptake Inhibitors

Urology — Mon, 14 Feb 2011 00:00:00 +0100

Conclusions: Tadalafil 20-mg treatment significantly improved sexual function in patients who were taking serotonin reuptake inhibitors for depression, with mild to moderate, well-tolerable adverse events. (Source: Urology)

Diary of a Manhattan sex therapist - Part 1

Psychology Today Sex Center — Thu, 03 Feb 2011 12:57:16 +0100

Want to test your knowledge of male sexual psychology? Take this quiz: QUIZ: It's Saturday night. Paul, 25 years old, is on a date with a new woman whom he likes very much and finds very sexy. Unfortunately, later that night when they undress together, he suddenly has no erection. She is very understanding and kind, and tells him it's OK. QUESTION: What will Paul most likely do in this situation?A. He'll feel reassured, and they'll go on to have a wonderful evening together.B. He'll go home very depressed and spend the rest of the night feverishly masturbating to prove to himself that he can still get hard. You all know the answer -- it's B, right? Loss ...

Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension

The Journal of Heart and Lung Transplantation — Mon, 24 Jan 2011 00:00:00 +0100

Conclusion: Tadalafil 40 mg was well-tolerated and provided clinical benefit in patients as monotherapy. It was also well-tolerated when added to background bosentan, but data are insufficient to conclude additional benefit. (Source: The Journal of Heart and Lung Transplantation)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1‐year, open‐label extension study

BJU International — Tue, 18 Jan 2011 00:00:00 +0100

CONCLUSIONSIn men with BPH‐LUTS, 5 mg of tadalafil once daily during 1 year of treatment was well tolerated and efficacy changes were maintained. (Source: BJU International)

Effect of Tipranavir/Ritonavir Combination on the Pharmacokinetics of Tadalafil in Healthy Volunteers.

The Journal of Clinical Pharmacology — Wed, 05 Jan 2011 00:00:00 +0100

This study evaluated the effects of single-dose administration and steady-state concentrations of tipranavir 500 mg and ritonavir 200 mg (TPV/r) combination on the pharmacokinetics of tadalafil 10 mg (TAD) in an open-label study. Seventeen healthy male volunteers received sequential dosing of the studied product: TAD (day 1) alone in a single dose for 7 days followed by TAD (day 8) in a single dose with TPV/r (500/200 mg twice daily, days 8-18). Pharmacokinetic parameters were determined in a non-compartmental analysis. The geometric mean ratio and 90% confidence interval were used to evaluate drug interactions. The effect of a single dose of TAD on the pharmacokinetics of TPV/r resulted in a small decrease in exposure after either first-dose or steady-state TPV/r (geometric mean ratios [9...

Brachial artery flow mediated assessment: A tool to predict the response to chronic PDE5 inhibition with tadalafil in patients with erectile dysfunction

International Journal of Cardiology — Mon, 03 Jan 2011 00:00:00 +0100

Impairment of cavernosal arteries responsiveness is the most common cause of erectile dysfunction (ED) whose pathogenesis primarily depends on vascular endothelial dysfunction . Atherosclerotic risk factors increase the rate of ED and most male patients with angiographically documented coronary artery disease (CAD) exhibit ED . (Source: International Journal of Cardiology)

Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action

Neurourology and Urodynamics — Sat, 01 Jan 2011 00:00:00 +0100

ConclusionsThe pathophysiology of male LUTS is complex and not completely understood. LUTS may occur independently of BPH or secondary to BPH but in both cases involve obstructive or irritative mechanisms with substantial pathophysiological overlap. While the precise mechanism remains unclear, inhibition of PDE5 seems to have an effect on several pathways that may impact LUTS. © 2011 Wiley‐Liss, Inc. (Source: Neurourology and Urodynamics)

Patients’ preference in the treatment of erectile dysfunction: a critical review of the literature

International Journal of Impotence Research — Thu, 30 Dec 2010 00:00:00 +0100

Patients’ preference in the treatment of erectile dysfunction: a critical review of the literature International Journal of Impotence Research advance online publication, December 30, 2010. doi:10.1038/ijir.2010.29 Authors: A Martin Morales, M Casillas & C Turbi (Source: International Journal of Impotence Research)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Exposure to Phosphodiesterase Type 5 Inhibitors Stimulates Aromatase Expression in Human Adipocytes in vitro

The Journal of Sexual Medicine — Wed, 22 Dec 2010 00:00:00 +0100

Conclusions. Our results demonstrate that PDE5 is expressed in human visceral adipocytes and that acute exposure to PDE5i selectively stimulates ARO expression, which is related to a specific PDE5 blockade. We speculate that modulation of ARO activity by PDE5i could be one of the mechanisms responsible, at least in part, for the beneficial effects of PDE5i on endothelial and metabolic functions. Aversa A, Caprio M, Antelmi A, Armani A, Brama M, Greco EA, Francomano D, Calanchini M, Spera G, Luigi LD, Rosano GMC, Lenzi A, Migliaccio S, and Fabbri A. Exposure to phosphodiesterase type‐5 inhibitors stimulates aromatase expression in human adipocytes in vitro. J Sex Med **;**:**–**. (Source: The Journal of Sexual Medicine)

Design, Synthesis and Structure–Activity Relationship of Functionalized Tetrahydro‐β‐carboline Derivatives as Novel PDE5 Inhibitors

Archiv der Pharmazie — Wed, 22 Dec 2010 00:00:00 +0100

AbstractStarting from tadalafil as a template, a series of functionalized tetrahydro‐β‐carboline derivatives have been prepared and identified as novel potent and selective PDE5 inhibitors. Replacing the 3,4‐methylenedioxyphenyl at position 6 of tadalafil, together with elongation of the N2‐methyl substituent and manipulation of the stereochemical aspects of the two chiral carbons led to the identification of compound XXI, a highly potent PDE5 inhibitor (IC50 = 3 nM). Compound XXI was also highly selective for PDE5 versus PDE3B, PDE4B, and PDE11A, with a selectivity index of 52 and 235 towards PDE5 rather than PDE11 with both cAMP and cGMP as substrate, respectively.PDE5 has been successfully targeted for treatment of male erectile dysfunction. Herein we report the synthesis o...

Molecule Page: Phosphodiesterase 5A, cGMP specific

Nature Signaling Update — Mon, 20 Dec 2010 02:37:05 +0100

PDE5A is a cyclic nucleotide phosphodiesterase (PDE) that specifically catalyses the hydrolysis of the phosphodiester bond of 3',5'-cyclic GMP. It is a homodimer composed of two ~100 kDa subunits, each of which contains a regulatory and a catalytic domain. PDE5 is phosphorylated by PKG or PKA and phosphorylation is stimulated by allosteric cGMP binding. Phosphorylation of PDE5 occurs in intact cells when cGMP is elevated. This increases the affinity of allosteric cGMP binding as well as increasing both the affinity of the catalytic site for the cGMP substrate and the rate of cGMP hydrolysis. PDE5 is potently inhibited by vardenafil (Levitra), tadalafil (Cialis) and sildenafil (Viagra and Revatio) - medications that are used clinically for treatment of erectile dysfunction and pulmonary hyp...

Onset of efficacy of tadalafil once daily in men with erectile dysfunction: A randomized, ...

UroToday — Wed, 15 Dec 2010 23:00:00 +0100

Cooper University Medical Center, Camden, New Jersey. (Source: UroToday)

The Beneficial Effects of Tadalafil on Renal Ischemia-Reperfusion Injury in Rats

Urologia Internationalis : Last 20 articles — Wed, 15 Dec 2010 23:00:00 +0100

Urol Int (DOI:10.1159/000321927) (Source: Urologia Internationalis : Last 20 articles)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Comparison of the First Intake of Vardenafil and Tadalafil in Patients with Diabetic Neuropathy and Diabetic Erectile Dysfunction

The Journal of Sexual Medicine — Wed, 08 Dec 2010 00:00:00 +0100

Conclusions. In this study design, tadalafil and vardenafil are equally effective with the first intake in patients with diabetes and DN. Baseline indicators of erectile dysfunction and the ones verifying the effect of the treatment show significant correlation with the DN indicator—NDS. Tadalafil and vardenafil are well tolerated with no serious side effects. Kamenov ZA. Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction. J Sex Med **;**:**–**. (Source: The Journal of Sexual Medicine)

Retired Pharmacist Receives Nine Month Prison Sentence For Illegal Advertisement Of Prescription Only Medicines Online

Health News from Medical News Today — Mon, 06 Dec 2010 09:00:00 +0100

A 60-year-old man has been sentenced to nine months imprisonment suspended for two years and ordered to serve 150 hours of unpaid community work for illegally advertising prescription only medicines online. William John Parsons, a retired pharmacist from Fallowfield, Manchester, was found guilty by a Southwark Crown Court jury on 5 November 2010 of advertising prescription only medicines namely Viagra, Cialis and Levitra... (Source: Health News from Medical News Today)

A New Online Pharmacy rxbuys.com by RX Corp Offers its Services to...

PRWeb: Medical Pharmaceuticals — Sat, 04 Dec 2010 07:53:29 +0100

New clients are invited to use the services of a web pharmacy that has been created recently to provide customers with the most popular drugs, like generic Cialis, for the most competitive prices.(PRWeb December 03, 2010)Read the full story at http://www.prweb.com/releases/2010/12/prweb4861124.htm (Source: PRWeb: Medical Pharmaceuticals)

The Oxygen Consumption-on Kinetics in The Sub Anaerobic Threshold Constant Load Exercises For Endothelium-dependent Vasodilatation Evaluating in the Muscle Microcirculation

Artery Research — Wed, 01 Dec 2010 00:00:00 +0100

Vasodilatation in the muscle microcircle was evaluated using VO2on kinetics in constant load cycle ergometer exercise, at load less of 10% than that corresponding to anaerobic threshold in previous incremental test identified. At onset of this constant load exercise, VO2 increases early and fast [first phase (φI)]; it follows a slower increase [second phase (φII)], which appears with variable delay, and reaches in about 3 minutes steady-state [third phase (φIII)] by single exponential function. We excluded φI from our measurements because invalided by many fakes. ΨII was attributed to O2 decreased content in active muscles blood, where this undergoes a gas exchange. ΨII time constant (τ) can be decreased by exercise training so as heart disease therapy, whereas heart diseases prolon...

Tadalafil Promptly Helps Restore Erectile Function

Medscape Pharmacist Headlines — Mon, 29 Nov 2010 21:06:06 +0100

Within days of starting treatment, tadalafil (Cialis, Lilly) can act against erectile dysfunction, researchers report in an advance online paper to appear in the Journal of Urology in January of 2011. Reuters Health Information (Source: Medscape Pharmacist Headlines)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Placebo Helps Improve Sexual Satisfaction In Women, Study Finds

Health News from Medical News Today — Wed, 17 Nov 2010 12:00:00 +0100

Women who took a placebo during a clinical trial measuring sexual satisfaction experienced improvements in symptoms such as low sex drive, according to a study published in the September issue of the Journal of Sexual Medicine, USA Today reports. The findings suggests that simply by taking action or feeling more hopeful about their sex lives, the women experienced improved satisfaction, the authors said. Researchers at the University of Texas-Austin Sexual Psychophysiology Laboratory used data collected during a clinical trial to test the erectile dysfunction drug Cialis in women... (Source: Health News from Medical News Today)

Onset of Efficacy of Tadalafil Once Daily in Men With Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Trial

The Journal of Urology — Mon, 15 Nov 2010 00:00:00 +0100

Purpose: We evaluated the efficacy onset and safety of tadalafil 2.5 and 5 mg once daily for 14 days compared with placebo in men with erectile dysfunction.Materials and Methods: In this randomized, double-blind, placebo controlled, parallel group study we randomized 372 men after a 4-week run-in period to receive placebo, or tadalafil 2.5 or 5 mg once daily for 14 days, followed by a 14-day open label extension period of tadalafil 5 mg once daily. Primary analysis focused on the cumulative percent of men with a successful intercourse attempt during the first 4 days of treatment. On secondary analysis we evaluated the percent of successful attempts during the study. The Sexual Encounter Profile diary question 3 was used to assess efficacy. Safety was assessed by monitoring adverse events a...

Measurement Properties of the Benign Prostatic Hyperplasia Impact Index in Tadalafil Studies

Health and Quality of Life Outcomes — Fri, 12 Nov 2010 00:00:00 +0100

Background: To assess the measurement properties of the Benign Prostatic Hyperplasia Impact Index (BII) for use in men with Lower Urinary Tract Symptoms (LUTS) secondary to Benign Prostatic Hyperplasia (BPH) treated with tadalafil. Methods: Data from a dose-titration (Study 1) and a dose-finding placebo-controlled (Study 2) tadalafil studies of men 45 years of age or older with moderate to severe LUTS (N=281; N=1053) were included in this post-hoc analysis. Measures included the BII, International Prostate Symptom Score (IPSS), IPSS Quality of Life Index (IPSS-QoL), LUTS Global Assessment Question, uroflowmetry measure peak flow rate (Qmax) and postvoid residual volume (PVR). Spearman rank and Pearson correlation coefficients were computed between the BII score and the other measures at ea...

Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial

Rheumatology — Fri, 12 Nov 2010 00:00:00 +0100

Conclusion. Tadalafil as add-on therapy improves symptoms of RP, heals and prevents new DUs and improves QoL in patients with resistant secondary RP. Trial Registration. Clinicaltrials.gov, http://clinicaltrials.gov/, identifier: NCT00626665. (Source: Rheumatology)

Healing Erectile Dysfunction

Psychology Today Sex Center — Thu, 11 Nov 2010 20:38:03 +0100

Are you a man struggling with erectile problems? You may believe that you will have difficulty with this forever or that is not solvable unless you take medication for the problem but a pill may not fix all of the trouble. Here's why.... For most men, erectile problems are caused by an anxiety issue, not a medical issue. While prescriptions such as Viagra, Levitra and Cialis may help to solve the problem of getting your penis hard, you may not get to the core of why your penis is having difficulty getting hard in the first place. By then you are committed to taking prescriptions and "timing" when we are sexual for the rest of your sexual relationship. Getting to the core of the anxiety and taking back control of your body is what we will be discussing in this article.Keep in mind that the ...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Erectile Dysfunction Drug Could Improve Raynaud's Symptoms Associated With Scleroderma

Health News from Medical News Today — Tue, 09 Nov 2010 10:00:00 +0100

Adding tadalafil (Cialis®; Adcirca®) to the treatment of people with scleroderma can improve Raynaud's phenomenon symptoms and heal and prevent hand and finger ulcers associated with it, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta. Scleroderma (more formally called systemic sclerosis) is a rheumatic disease that results in the thickening and tightening of skin, as well as a build-up of scar tissue and damage to internal organs... (Source: Health News from Medical News Today)

Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia

BJU International — Fri, 05 Nov 2010 00:00:00 +0100

CONCLUSIONSUdenafil and tadalafil significantly increased cAMP and cGMP levels and were more highly distributed in the prostate than plasma. The T/P ratio of udenafil was higher than tadalafil. These findings may help in the assessment of the feasibility of using PDE5 Is to concurrently treat both LUTS and erectile dysfunction. (Source: BJU International)

The Impact of Oral ED Medication on Female Partners' Relationship Satisfaction

The Journal of Sexual Medicine — Wed, 03 Nov 2010 00:00:00 +0100

Conclusions. This study demonstrates the positive effects of treatment for ED on the female partner; in particular, on her perception of the quality of her relationship. McCabe MP, O'Connor EJ, Conaglen JV, and Conaglen HM. The impact of oral ED medication on female partners' relationship satisfaction. J Sex Med **;**:**–**. (Source: The Journal of Sexual Medicine)

Protective effect of tadalafil on ischemia/reperfusion injury of rat ovary

Journal of Pediatric Surgery — Fri, 29 Oct 2010 22:28:21 +0100

Conclusions: Tadalafil is effective in preventing tissue damage induced by I/R in rat ovaries. (Source: Journal of Pediatric Surgery)